HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Topical benzoyl peroxide products

This article was originally published in The Rose Sheet

Executive Summary

FDA is predicting a July publication date for a notice of proposed rulemaking on the labeling of topical drug products containing benzoyl peroxide, according to the agency's regulatory agenda published in the Federal Register April 25. Also in July, FDA anticipates completing final action on an addendum to the skin protectant monograph involving witch hazel. The dates for final rules on anticaries and skin bleaching products have been pushed back to September

FDA is predicting a July publication date for a notice of proposed rulemaking on the labeling of topical drug products containing benzoyl peroxide, according to the agency's regulatory agenda published in the Federal Register April 25. Also in July, FDA anticipates completing final action on an addendum to the skin protectant monograph involving witch hazel. The dates for final rules on anticaries and skin bleaching products have been pushed back to September.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel